Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.69 |
| ▸ | THRA | P10827 | 14/20 | 0.38 |
| ▸ | THRB | P10828 | 14/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7053405 | 0.91 | NR3C1 (0.68) | NR3C1THRATHRBABL1RIN1 | |
| SCHEMBL7253471 | 0.91 | NR3C1 (0.82) | NR3C1THRATHRBALOX15TSHR | |
| SCHEMBL5630623 | 0.91 | NR3C1 (0.85) | NR3C1THRATHRBABL1RIN1 | |
| SCHEMBL7053915 | 0.89 | NR3C1 (0.61) | NR3C1THRATHRBLMNA | |
| SCHEMBL7053515 | 0.88 | NR3C1 (0.72) | NR3C1THRATHRBLMNA | |
| SCHEMBL7051558 | 0.88 | NR3C1 (0.59) | NR3C1THRATHRB | |
| SCHEMBL7050206 | 0.87 | NR3C1 (0.62) | NR3C1THRATHRB | |
| SCHEMBL7687151 | 0.87 | NR3C1 (0.62) | NR3C1THRATHRB | |
| SCHEMBL7052767 | 0.87 | NR3C1 (0.62) | NR3C1THRATHRB | |
| SCHEMBL7681978 | 0.86 | NR3C1 (0.71) | NR3C1THRATHRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166725-A1 | Compounds active at the glucocorticoid receptor | KARO BIO AB (SE) | 2003-09-04 | — | — | US | disclosed |
| EP-1265839-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| WO-2002044120-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR III | KARO BIO AB (SE) | 2002-06-06 | — | — | WO | disclosed |
| WO-2001047859-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166725-A1 | Compounds active at the glucocorticoid receptor | NR3C1, NR3C2, GPR119 | NR3C1 1/4885THRA 291/4885THRB 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.